Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Risks and implications of multiple actionable pathogenic germline variants discovered by panel-based cancer predisposition testing.
Authors
Michael J. Hall
Fox Chase Cancer Center, Philadelphia, PA;
Michael J. Hall , Michelle J McSweeny , Kim Rainey , Hannah Campbell , Chau Nguyen , Catherine Neumann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Prevention, Screening, and Hereditary Cancers
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 792)
DOI
10.1200/JCO.2023.41.4_suppl.792
Abstract #
792
Poster Bd #
M7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Co-occurrence of germline pathogenic variants in Chinese patients with solid tumors.
First Author: Yan Zhang
Poster
2022 ASCO Genitourinary Cancers Symposium
Hereditary cancer risk assessment in the community urology practice setting.
First Author: Neal D. Shore
Poster
2024 ASCO Annual Meeting
Pathogenic germline variant discovery in plasma cell disorders: Insights from genetic counseling referrals and testing.
First Author: Saoirse Bodnar
Poster
2023 ASCO Annual Meeting
Validation of a guidelines-based brief patient-administered digital tool to assess the need for germline genetic testing.
First Author: Callan Russell